The introduction of CFTR modulator therapies designed to correct and potentiate CFTR in cholangiocytes, endothelial cells, and platelets aims to impede or arrest the progression of CFLD [69]. This evidence concerns the gene CFTR and cystic fibrosis-related liver disease.